Tumor Neoantigen (Patient-Specific)

Tumor neoantigens are unique, patient-specific antigens that arise from somatic mutations in tumor cells. These mutations lead to the production of novel peptides not present in normal tissues. These peptides can be recognized by T cells, triggering a targeted immune response against cancer cells. They offer a highly specific target for personalized cancer therapies due to their absence in healthy tissues. Identification relies heavily on advanced genomics technologies coupled with computational prediction tools followed by functional validation. Their use is at the forefront of precision oncology through personalized vaccine development and adoptive cellular therapies.

Other names

NeoantigenTumor-specific antigenMutated self-antigen

T-cell mediated killing of tumor cells